<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>SW-Listed — Portfolio on 6ix</title>
<link>https://6ix.com/p/sw-listed</link>
<description>Top companies trading on SW, ranked by market cap.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 20:54:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/portfolio/sw-listed" rel="self" type="application/rss+xml" />
<item>
<title>WISeKey Reports Audited Full Year 2025 Financial Results</title>
<link>https://6ix.com/news/wisekey-reports-audited-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/news/wisekey-reports-audited-full-year-2025-financial-results</guid>
<pubDate>Thu, 30 Apr 2026 20:54:00 GMT</pubDate>
<description>WISeKey Reports Audited Full Year 2025 Financial Results Schedules Conference Call for Monday, May 4 at 9:00am EDT Audited FY 2025 revenue of $19.3 million, representing 62% growth year-over-yearSubsidiary SEALSQ reported 66% year-over-year revenue growth Reaffirms FY 2026 guidance with revenue expected to grow between 50%-100% year-over-year; Q1 2026 unaudited revenue of $4.2 millionStrong cash and short-term investments of over $535 million as of April 30, 2026, well positions the WISeKey Grou</description>
</item>
<item>
<title>Alcon Ag: Alcon Announces Results of 2026 Annual General Meeting</title>
<link>https://6ix.com/company/alcon-ag/news/alcon-announces-results-of-2026-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/alcon-ag/news/alcon-announces-results-of-2026-annual-general-meeting</guid>
<pubDate>Thu, 30 Apr 2026 20:30:00 GMT</pubDate>
<description>GENEVA, April 30, 2026--Alcon Announces Results of 2026 Annual General Meeting</description>
</item>
<item>
<title>UBS hires Financial Advisor Luke Naes in Boulder, Colorado</title>
<link>https://6ix.com/news/ubs-hires-financial-advisor-luke-naes-in-boulder-colorado</link>
<guid isPermaLink="true">https://6ix.com/news/ubs-hires-financial-advisor-luke-naes-in-boulder-colorado</guid>
<pubDate>Thu, 30 Apr 2026 14:42:00 GMT</pubDate>
<description>BOULDER, Colo., April 30, 2026--UBS today announced that Luke Naes has joined the firm as a Financial Advisor in its Boulder, Colorado office. He joins the UBS Mountain West Market, led by Market Executive Mitch Markley and Senior Market Director Tyler Hutchens.</description>
</item>
<item>
<title>Novartis Ag: Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility</title>
<link>https://6ix.com/company/novartis-ag/news/novartis-finalizes-us-manufacturing-and-randd-expansion-plan-with-seventh-new-facility</link>
<guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-finalizes-us-manufacturing-and-randd-expansion-plan-with-seventh-new-facility</guid>
<pubDate>Thu, 30 Apr 2026 11:00:00 GMT</pubDate>
<description>At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced technology platforms in US – a first in company’s history Basel, April 30, 2026 – Novartis today announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage</description>
</item>
<item>
<title>Compagnie Financiere Tradition: Q1 2026: Revenue growth of 17.4% at constant exchange rates to CHF 339.7m</title>
<link>https://6ix.com/company/compagnie-financiere-tradition/news/q1-2026-revenue-growth-of-174percent-at-constant-exchange-rates-to-chf-3397m</link>
<guid isPermaLink="true">https://6ix.com/company/compagnie-financiere-tradition/news/q1-2026-revenue-growth-of-174percent-at-constant-exchange-rates-to-chf-3397m</guid>
<pubDate>Thu, 30 Apr 2026 05:20:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LRDownload PDF - EN Lausanne, Switzerland--(Newsfile Corp. - April 30, 2026) - Ad hoc announcement pursuant to Article 53 of the Six Exchange Regulation Listing Rules Q1 2026: Revenue1) growth of 17.4% at constant exchange ratesto CHF 339.7m Compagnie Financière Tradition continued the positive momentum observed in previous financial years, reporting sustained growth in its activities at constant exchange rates in the first quarter ...</description>
</item>
<item>
<title>Compagnie Financiere Tradition: Notice of the Ordinary General Meeting of Compagnie Financière Tradition SA</title>
<link>https://6ix.com/company/compagnie-financiere-tradition/news/notice-of-the-ordinary-general-meeting-of-compagnie-financiere-tradition-sa</link>
<guid isPermaLink="true">https://6ix.com/company/compagnie-financiere-tradition/news/notice-of-the-ordinary-general-meeting-of-compagnie-financiere-tradition-sa</guid>
<pubDate>Thu, 30 Apr 2026 05:19:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LRDownload PDF - EN Lausanne, Switzerland--(Newsfile Corp. - April 30, 2026) - Ad hoc announcement pursuant to Article 53 of the Six Exchange Regulation Listing Rules Compagnie Financière Tradition’s annual general meeting will be held on Thursday, 21 May 2026 at 3.30 pm at the Hotel Beau-Rivage Palace, Lausanne. Notice of the meeting with the agenda and proposals of the Board of Directors will be published on 30 April 2026 in the...</description>
</item>
<item>
<title>Santhera Pharmaceuticals Holding Ag: Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors</title>
<link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-proposes-dr-srishti-gupta-as-new-member-of-the-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-proposes-dr-srishti-gupta-as-new-member-of-the-board-of-directors</guid>
<pubDate>Thu, 30 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, April 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Srishti Gupta, MD, MPP, MPhil, as an Independent Director at the upcoming Annual General Meeting to be held on May 26, 2026. Thomas Meier, Chairman of the Board, said: “Dr. Gupta has a wealth of experience in building and leading successful businesses, and we are delighted she has agreed to be nominated to join the Board. Her depth of experience as a phys</description>
</item>
<item>
<title>Addex Therapeutics Ltd: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-reports-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-reports-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 30 Apr 2026 05:00:00 GMT</pubDate>
<description>GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury recoveryEntered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryRegained rights to phase 2 mGlu2 PAM asset, ADX71149Partner, Indivior advanced GABAB PAM substance use disorders program successfully t</description>
</item>
<item>
<title>Landis+gyr Group Ag: Landis+Gyr Announces Sale of Rhebo to Everfield</title>
<link>https://6ix.com/company/landisgyr-group-ag/news/landisgyr-announces-sale-of-rhebo-to-everfield</link>
<guid isPermaLink="true">https://6ix.com/company/landisgyr-group-ag/news/landisgyr-announces-sale-of-rhebo-to-everfield</guid>
<pubDate>Thu, 30 Apr 2026 04:45:00 GMT</pubDate>
<description>Landis+Gyr Group AG (SIX: LAND), a global energy technology leader driving intelligent innovation across the grid, today announced it has signed a definitive agreement to sell Rhebo GmbH to Everfield Germany GmbH, a buy-and-hold investor in European B2B SaaS businesses. Completion of the transaction remains subject to customary regulatory approvals and other standard closing conditions.</description>
</item>
<item>
<title>Bachem Holding Ag: Bachem Annual General Meeting 2026</title>
<link>https://6ix.com/company/bachem-holding-ag/news/bachem-annual-general-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bachem-holding-ag/news/bachem-annual-general-meeting-2026</guid>
<pubDate>Wed, 29 Apr 2026 16:09:00 GMT</pubDate>
<description>All proposals of the Board of Directors approved. Dividend of CHF 0.90 per share. Bubendorf, Switzerland--(Newsfile Corp. - April 29, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) announced today that its Annual General Meeting 2026 has approved all proposals of the Board of Directors. A total of 78,3% of the 74‘977‘940 eligible shares were present. The Annual General Meeting approved a dividend of CHF 0.90 per share. The dividend will be paid on May 6, 2026. The...</description>
</item>
<item>
<title>Nestlé S.a.: Nestlé Joins the Microbiome Therapeutics Innovation Group (MTIG); Krys Araujo‑Torres, MD, MPP to Represent Company</title>
<link>https://6ix.com/company/nestle-sa/news/nestle-joins-the-microbiome-therapeutics-innovation-group-mtig-krys-araujotorres-md-mpp-to-represent-company</link>
<guid isPermaLink="true">https://6ix.com/company/nestle-sa/news/nestle-joins-the-microbiome-therapeutics-innovation-group-mtig-krys-araujotorres-md-mpp-to-represent-company</guid>
<pubDate>Wed, 29 Apr 2026 12:00:00 GMT</pubDate>
<description>Nestlé today announced it has joined the Microbiome Therapeutics Innovation Group (MTIG), an independent coalition advancing FDA‑approved microbiome therapeutics and microbiome‑based products. MTIG works to enhance the regulatory, investment, and commercial environment to accelerate development and expand patient access to life‑changing microbiome medicines.</description>
</item>
<item>
<title>Addex Therapeutics Ltd: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model</title>
<link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-solid-anti-tussive-activity-in-bleomycin-ipf-related-chronic-cough-model</link>
<guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-solid-anti-tussive-activity-in-bleomycin-ipf-related-chronic-cough-model</guid>
<pubDate>Wed, 29 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chr</description>
</item>
<item>
<title>UBS reports USD 3.0bn net profit and 16.8% RoCET1 in 1Q26 driven by strong client activity and flows; on track to complete integration by year-end (Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules)</title>
<link>https://6ix.com/news/ubs-reports-usd-30bn-net-profit-and-168percent-rocet1-in-1q26-driven-by-strong-client-activity-and-flows-on-track-to-complete-integration-by-year-end-ad-hoc-announcement-pursuant-to-article-53-of-the-six-exchange-regulation-listing-rules</link>
<guid isPermaLink="true">https://6ix.com/news/ubs-reports-usd-30bn-net-profit-and-168percent-rocet1-in-1q26-driven-by-strong-client-activity-and-flows-on-track-to-complete-integration-by-year-end-ad-hoc-announcement-pursuant-to-article-53-of-the-six-exchange-regulation-listing-rules</guid>
<pubDate>Wed, 29 Apr 2026 04:45:00 GMT</pubDate>
<description>ZURICH, April 29, 2026--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428614015/en/</description>
</item>
<item>
<title>Givaudan Sa: PepsiCo, Givaudan, Smurfit Westrock and Statkraft Sign 10‑Year Renewable Energy Agreement to Advance Value Chain Decarbonization Across Europe</title>
<link>https://6ix.com/company/givaudan-sa/news/pepsico-givaudan-smurfit-westrock-and-statkraft-sign-10year-renewable-energy-agreement-to-advance-value-chain-decarbonization-across-europe-1</link>
<guid isPermaLink="true">https://6ix.com/company/givaudan-sa/news/pepsico-givaudan-smurfit-westrock-and-statkraft-sign-10year-renewable-energy-agreement-to-advance-value-chain-decarbonization-across-europe-1</guid>
<pubDate>Tue, 28 Apr 2026 13:00:00 GMT</pubDate>
<description>PepsiCo (NASDAQ: PEP), Givaudan, Smurfit WestRock and Statkraft have announced a 10‑year Virtual Power Purchase Agreement (VPPA) with an underlying wind asset in Spain which is undergoing repowering. The agreement strengthens progress toward shared sustainability goals</description>
</item>
<item>
<title>Temenos Group Ag: Temenos Named a Leader in Digital Banking Engagement Platforms</title>
<link>https://6ix.com/company/temenos-group-ag/news/temenos-named-a-leader-in-digital-banking-engagement-platforms</link>
<guid isPermaLink="true">https://6ix.com/company/temenos-group-ag/news/temenos-named-a-leader-in-digital-banking-engagement-platforms</guid>
<pubDate>Tue, 28 Apr 2026 07:02:00 GMT</pubDate>
<description>Temenos recognized for its strong out-of-the-box solutions and multi-channel support, supporting banks in every regionGRAND-LANCY, Switzerland, April 28, 2026 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), a global leader in banking technology, today announced it has been named a Leader in the Forrester Wave™: Digital Banking Engagement Platforms, Q2 2026. The report, which scored vendors against 30 criteria relating to both their current offering and strategy, stated: “Temenos offers robust out-of-th</description>
</item>
<item>
<title>Logitech International S.a.: Introducing the Logitech G512 X Gaming Keyboard: Designed to be Tuned, Tweaked, and Mastered for Personalized Performance</title>
<link>https://6ix.com/company/logitech-international-sa/news/introducing-the-logitech-g512-x-gaming-keyboard-designed-to-be-tuned-tweaked-and-mastered-for-personalized-performance</link>
<guid isPermaLink="true">https://6ix.com/company/logitech-international-sa/news/introducing-the-logitech-g512-x-gaming-keyboard-designed-to-be-tuned-tweaked-and-mastered-for-personalized-performance</guid>
<pubDate>Tue, 28 Apr 2026 07:01:00 GMT</pubDate>
<description>LAUSANNE, Switzerland & SAN JOSE, Calif., April 28, 2026--Logitech G today announced the new Logitech G512 X TMR Analog/Mechanical Gaming Keyboard.</description>
</item>
<item>
<title>Zurich launches Global Capability Center in Hyderabad to power next-gen tech and AI</title>
<link>https://6ix.com/news/zurich-launches-global-capability-center-in-hyderabad-to-power-next-gen-tech-and-ai</link>
<guid isPermaLink="true">https://6ix.com/news/zurich-launches-global-capability-center-in-hyderabad-to-power-next-gen-tech-and-ai</guid>
<pubDate>Tue, 28 Apr 2026 06:30:00 GMT</pubDate>
<description>Zurich Insurance Group (Zurich) today announced the launch of a new Global Capability Center in Hyderabad, reinforcing its focus on advancing technology and AI capabilities to transform insurance.</description>
</item>
<item>
<title>Santhera Pharmaceuticals Holding Ag: Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy</title>
<link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-positive-aifa-board-decision-on-reimbursement-of-agamreer-vamorolone-in-italy</link>
<guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-announces-positive-aifa-board-decision-on-reimbursement-of-agamreer-vamorolone-in-italy</guid>
<pubDate>Tue, 28 Apr 2026 05:01:00 GMT</pubDate>
<description>Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE® (vamorolone) for the treatment of patients with Duchenne muscular dystrophy (DMD) aged 4 years and older in Italy. AGAMREE is a novel molecule designed to deliver the anti-inflammatory benefits typically associated with glucocorticoids while potentially reducing the risk of adverse effects linked to th</description>
</item>
<item>
<title>Santhera Pharmaceuticals Holding Ag: Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025</title>
<link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-pharmaceuticals-full-year-results-for-the-year-ended-31-december-2025</link>
<guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-pharmaceuticals-full-year-results-for-the-year-ended-31-december-2025</guid>
<pubDate>Tue, 28 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 28, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release AGAMREE® delivers strong growth as global expansion accelerates Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces its full year results for the year ended 31 December 2025. Dario Eklund, CEO of Santhera, said: “Our strong performance in 2025 reflects the continued momentum of AGAM</description>
</item>
<item>
<title>Idorsia Ltd: Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year</title>
<link>https://6ix.com/company/idorsia-ltd/news/idorsia-reports-strong-q1-2026-performance-with-74percent-quviviq-sales-growth-year-on-year</link>
<guid isPermaLink="true">https://6ix.com/company/idorsia-ltd/news/idorsia-reports-strong-q1-2026-performance-with-74percent-quviviq-sales-growth-year-on-year</guid>
<pubDate>Tue, 28 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next stepsCo-promotion of QUVIVIQ is being expanded across additional European markets to further accelerate growthPartnering discussions for TRYVIO™/JERAYGO™ are ongoing with several parties Allschwil, Switzerland – April 28, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-cl</description>
</item>
<item>
<title>Novartis Ag: Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed</title>
<link>https://6ix.com/company/novartis-ag/news/novartis-delivered-strong-growth-in-priority-brands-and-launches-in-q1-fy-2026-guidance-reaffirmed</link>
<guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-delivered-strong-growth-in-priority-brands-and-launches-in-q1-fy-2026-guidance-reaffirmed</guid>
<pubDate>Tue, 28 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority brands including Kisqali (+55% cc), Pluvicto (+70% cc), Kesimpta (+26% cc), Scemblix (+79% cc) and Leqvio (+69% cc)Core operating income1 down -14% (cc, -12% USD), due to lower net sales and higher R&D investmentCore operating income margin1 was 37.3%Operating income declined -11% (cc, -9% USD); net i</description>
</item>
<item>
<title>Logitech International S.a.: Logitech Appoints Robin Piispanen as Global Head of Logitech G</title>
<link>https://6ix.com/company/logitech-international-sa/news/logitech-appoints-robin-piispanen-as-global-head-of-logitech-g</link>
<guid isPermaLink="true">https://6ix.com/company/logitech-international-sa/news/logitech-appoints-robin-piispanen-as-global-head-of-logitech-g</guid>
<pubDate>Mon, 27 Apr 2026 20:05:00 GMT</pubDate>
<description>LAUSANNE, Switzerland & SAN JOSE, Calif., April 27, 2026--Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced the appointment of Robin Piispanen as Global Head of Logitech G, the company's gaming business, effective May 4, 2026. Piispanen's appointment follows the planned retirement of Ujesh Desai, who has served as the division's global leader since 2014.</description>
</item>
<item>
<title>Novartis Ag: Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria</title>
<link>https://6ix.com/company/novartis-ag/news/novartis-rhapsidor-receives-european-commission-approval-as-first-oral-targeted-treatment-for-chronic-spontaneous-urticaria</link>
<guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-rhapsidor-receives-european-commission-approval-as-first-oral-targeted-treatment-for-chronic-spontaneous-urticaria</guid>
<pubDate>Mon, 27 Apr 2026 05:15:00 GMT</pubDate>
<description>Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido recommended in 2026 International Urticaria Guideline for all patients who remain symptomatic after H1-antihistamine treatment2CSU affects nearly 4 million people in Europe; more than 50% continue to experience debilitating symptoms after conventional antihistamine therapy3-5 Basel, April 27, 2026 – Novartis announced today that the Eur</description>
</item>
<item>
<title>Bachem Holding Ag: Bachem Secures Financing of Strategic Growth Initiatives</title>
<link>https://6ix.com/company/bachem-holding-ag/news/bachem-secures-financing-of-strategic-growth-initiatives</link>
<guid isPermaLink="true">https://6ix.com/company/bachem-holding-ag/news/bachem-secures-financing-of-strategic-growth-initiatives</guid>
<pubDate>Mon, 27 Apr 2026 05:03:00 GMT</pubDate>
<description>Media Release Bubendorf, Switzerland--(Newsfile Corp. - April 27, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) announced today the closing of a revolving credit facility of CHF 500 million with a maturity of five years and a non-committed option to increase the facility by CHF 150 million. The revolving credit facility was syndicated with UBS Switzerland AG acting as lead arranger and agent, together with a consortium of domestic and...</description>
</item>
<item>
<title>Santhera Pharmaceuticals Holding Ag: Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU</title>
<link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-receives-positive-chmp-opinion-to-expand-agamreer-vamorolone-use-in-pediatric-dmd-patients-aged-two-and-older-in-the-eu</link>
<guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-receives-positive-chmp-opinion-to-expand-agamreer-vamorolone-use-in-pediatric-dmd-patients-aged-two-and-older-in-the-eu</guid>
<pubDate>Mon, 27 Apr 2026 05:00:00 GMT</pubDate>
<description>Pratteln, Switzerland, April 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an extension to the marketing authorization for AGAMREE® (vamorolone) to include the treatment of patients with Duchenne muscular dystrophy (DMD) from 2 years of age. AGAMREE is currently approved in the European Union for the treatment of DMD in patients 4 yea</description>
</item>
<item>
<title>Novartis Ag: Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)</title>
<link>https://6ix.com/company/novartis-ag/news/novartis-receives-positive-chmp-opinion-for-itvismar-for-spinal-muscular-atrophy-sma</link>
<guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-receives-positive-chmp-opinion-for-itvismar-for-spinal-muscular-atrophy-sma</guid>
<pubDate>Fri, 24 Apr 2026 10:30:00 GMT</pubDate>
<description>If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma demonstrated clinically meaningful and statistically significant improvement in motor function in Phase III STEER studyOne-time dose of Itvisma replaces SMN1 gene, with potential to reduce need for chronic SMA treatment Basel, April 24, 2026 – Novartis today announced that the Committee for Medicinal P</description>
</item>
<item>
<title>Novartis Ag: Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants</title>
<link>https://6ix.com/company/novartis-ag/news/novartis-malaria-treatment-coartemr-baby-receives-who-prequalification-paving-way-for-greater-access-for-newborns-and-young-infants</link>
<guid isPermaLink="true">https://6ix.com/company/novartis-ag/news/novartis-malaria-treatment-coartemr-baby-receives-who-prequalification-paving-way-for-greater-access-for-newborns-and-young-infants</guid>
<pubDate>Fri, 24 Apr 2026 05:15:00 GMT</pubDate>
<description>Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agenciesNovartis making treatment available on largely not-for-profit basis in areas where malaria is endemic East Hanover, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemethe</description>
</item>
<item>
<title>Addex Therapeutics Ltd: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026</title>
<link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-spin-out-company-neurosterix-on-track-to-complete-phase-1-clinical-study-of-ntx-253-for-schizophrenia-in-q2-2026</link>
<guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-spin-out-company-neurosterix-on-track-to-complete-phase-1-clinical-study-of-ntx-253-for-schizophrenia-in-q2-2026</guid>
<pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allost</description>
</item>
<item>
<title>Nestlé S.a.: Three-month sales 2026: continued growth momentum</title>
<link>https://6ix.com/company/nestle-sa/news/three-month-sales-2026-continued-growth-momentum</link>
<guid isPermaLink="true">https://6ix.com/company/nestle-sa/news/three-month-sales-2026-continued-growth-momentum</guid>
<pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
<description>[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) Follow today's event live09:30 CEST Investor call audio webcastFull details on our website ............. Three-month sales 2026: continued growth momentum Philipp Navratil, Nestlé CEO, commented: “Our first-quarter performance demonstrates that our RIG-led growth strategy is delivering. Results were strong across most Zones and categories, particularly in Coffee and Food & Snacks</description>
</item>
<item>
<title>Santhera Pharmaceuticals Holding Ag: Santhera Appoints Orlando Oliveira as Chief Executive Officer</title>
<link>https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-appoints-orlando-oliveira-as-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/santhera-pharmaceuticals-holding-ag/news/santhera-appoints-orlando-oliveira-as-chief-executive-officer</guid>
<pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR. Dario Eklund to hand over leadership following planned transition Pratteln, Switzerland, April 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Orlando Oliveira as Chief Executive Officer (CEO), effective July 15, 2026. He succeeds Dario Eklund, who will step down after more than six and a half years as CEO and remains available during a transition period to support an orderly handover. Mr. Oliveira brings more than 25 years</description>
</item>
<item>
<title>Galderma Group N: Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-reports-strong-start-to-the-year-delivering-first-quarter-2026-net-sales-of-1473-billion-usd-growing-255percent-at-constant-currency</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-reports-strong-start-to-the-year-delivering-first-quarter-2026-net-sales-of-1473-billion-usd-growing-255percent-at-constant-currency</guid>
<pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
<description>ZUG, Switzerland, April 23, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026.</description>
</item>
<item>
<title>Temenos Group Ag: nCino Announces Nick Edwards as Managing Director for APAC</title>
<link>https://6ix.com/company/temenos-group-ag/news/ncino-announces-nick-edwards-as-managing-director-for-apac-1</link>
<guid isPermaLink="true">https://6ix.com/company/temenos-group-ag/news/ncino-announces-nick-edwards-as-managing-director-for-apac-1</guid>
<pubDate>Wed, 22 Apr 2026 21:30:00 GMT</pubDate>
<description>WILMINGTON, N.C. and SYDNEY, April 22, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the platform for agentic banking, today announced Nick Edwards as the new Managing Director for the APAC region. Edwards is a seasoned commercial and regional leader with deep expertise across financial services. With nearly two decades of experience across the region, he has developed an intimate understanding of the unique dynamics, customer needs and market opportunities that define financial services</description>
</item>
<item>
<title>Ascom Holding Ag: Laurent Dubois elected as new Chairman of the Board of Directors of Ascom</title>
<link>https://6ix.com/company/ascom-holding-ag/news/laurent-dubois-elected-as-new-chairman-of-the-board-of-directors-of-ascom</link>
<guid isPermaLink="true">https://6ix.com/company/ascom-holding-ag/news/laurent-dubois-elected-as-new-chairman-of-the-board-of-directors-of-ascom</guid>
<pubDate>Wed, 22 Apr 2026 16:02:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LRBaar, Switzerland, April 22, 2026At the Annual General Meeting held on April 22, 2026, in Zug, the shareholders of Ascom Holding AG approved all proposals from the Board of Directors by a large majority. 66 shareholders attended the Annual General Meeting. In total, 17’690’637 registered shares with voting rights were represented, corresponding to 49.14 % of the share capital. The annual financial statements and consolidated financial statements for the</description>
</item>
<item>
<title>Galderma Group N: Galderma Shareholders Approve All Annual General Meeting Proposals</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-shareholders-approve-all-annual-general-meeting-proposals</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-shareholders-approve-all-annual-general-meeting-proposals</guid>
<pubDate>Wed, 22 Apr 2026 15:45:00 GMT</pubDate>
<description>ZUG, Switzerland, April 22, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions.</description>
</item>
<item>
<title>UBS statement on regulatory capital announcements made by the Swiss government</title>
<link>https://6ix.com/news/ubs-statement-on-regulatory-capital-announcements-made-by-the-swiss-government</link>
<guid isPermaLink="true">https://6ix.com/news/ubs-statement-on-regulatory-capital-announcements-made-by-the-swiss-government</guid>
<pubDate>Wed, 22 Apr 2026 15:20:00 GMT</pubDate>
<description>ZURICH, April 22, 2026--Regulatory News: Ad hoc announcement pursuant to article 53 of the SIX Exchange Regulation Listing Rules</description>
</item>
<item>
<title>Abb Ltd: New 34.5kV HiPerGuard UPS: direct grid connection cuts AI data center power costs</title>
<link>https://6ix.com/company/abb-ltd/news/new-345kv-hiperguard-ups-direct-grid-connection-cuts-ai-data-center-power-costs</link>
<guid isPermaLink="true">https://6ix.com/company/abb-ltd/news/new-345kv-hiperguard-ups-direct-grid-connection-cuts-ai-data-center-power-costs</guid>
<pubDate>Tue, 21 Apr 2026 21:05:00 GMT</pubDate>
<description>ABB's new 34.5kV HiPerGuard UPS ABB unveils new voltage 34.5kV HiPerGuard UPS coming soon. ABB’s microgrid-ready UPS architecture Direct grid connection with ABB's 34.5kV HiPerGuard UPS reduces conversion losses and infrastructure complexity. Washington, D.C., USA, April 21, 2026 (GLOBE NEWSWIRE) -- ABB’s microgrid-ready UPS architecture integrates battery storage, renewables, and gas generation for resilience and flexibility for AI data centersDirect 34.5kV grid connection reduces conversion lo</description>
</item>
<item>
<title>Logitech International S.a.: Logitech Listed on SIX Swiss Exchange’s New Sustainability Index of 25 Leading Companies</title>
<link>https://6ix.com/company/logitech-international-sa/news/logitech-listed-on-six-swiss-exchanges-new-sustainability-index-of-25-leading-companies</link>
<guid isPermaLink="true">https://6ix.com/company/logitech-international-sa/news/logitech-listed-on-six-swiss-exchanges-new-sustainability-index-of-25-leading-companies</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>LAUSANNE, Switzerland & SAN JOSE, Calif., April 21, 2026--Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced its inclusion in the inaugural SPI® ESG 25 Index, introduced by SIX, the Swiss stock exchange operator. The SPI ESG 25 represents a focused subset of the broader SPI ESG Index, selecting 25 companies based on the highest combined scores in market capitalization, trading volume, and ESG Impact Ratings.</description>
</item>
<item>
<title>Nestlé S.a.: Keurig Dr Pepper and Nestlé USA Extend Strategic Partnership</title>
<link>https://6ix.com/company/nestle-sa/news/keurig-dr-pepper-and-nestle-usa-extend-strategic-partnership-2</link>
<guid isPermaLink="true">https://6ix.com/company/nestle-sa/news/keurig-dr-pepper-and-nestle-usa-extend-strategic-partnership-2</guid>
<pubDate>Tue, 21 Apr 2026 13:00:00 GMT</pubDate>
<description>Keurig Dr Pepper (KDP) and Nestlé USA (Nestlé) today announced an extended agreement renewing and expanding their strategic partnership, including the manufacturing and distribution of Starbucks® K-Cup® pods in the U.S. and Canada.</description>
</item>
<item>
<title>Lonza Group Ag: Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products</title>
<link>https://6ix.com/company/lonza-group-ag/news/simulations-plus-announces-collaboration-with-lonza-and-us-fda-to-advance-predictive-frameworks-for-complex-oral-drug-products-2</link>
<guid isPermaLink="true">https://6ix.com/company/lonza-group-ag/news/simulations-plus-announces-collaboration-with-lonza-and-us-fda-to-advance-predictive-frameworks-for-complex-oral-drug-products-2</guid>
<pubDate>Tue, 21 Apr 2026 11:55:00 GMT</pubDate>
<description>RESEARCH TRIANGLE PARK, N.C., April 21, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG ("Lonza"), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a mech</description>
</item>
<item>
<title>Addex Therapeutics Ltd: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model</title>
<link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-robust-anti-tussive-activity-in-non-human-primate-chronic-cough-model</link>
<guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-robust-anti-tussive-activity-in-non-human-primate-chronic-cough-model</guid>
<pubDate>Tue, 21 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. “These important data i</description>
</item>
<item>
<title>Sika Ag: SIKA EXPANDS ITS ACTIVITIES IN CENTRAL ASIA WITH A NEW NATIONAL SUBSIDIARY IN KYRGYZSTAN</title>
<link>https://6ix.com/company/sika-ag/news/sika-expands-its-activities-in-central-asia-with-a-new-national-subsidiary-in-kyrgyzstan-5</link>
<guid isPermaLink="true">https://6ix.com/company/sika-ag/news/sika-expands-its-activities-in-central-asia-with-a-new-national-subsidiary-in-kyrgyzstan-5</guid>
<pubDate>Tue, 21 Apr 2026 05:00:00 GMT</pubDate>
<description>SIKA EXPANDS ITS ACTIVITIES IN CENTRAL ASIA WITH A NEW NATIONAL SUBSIDIARY IN KYRGYZSTAN Sika is strengthening its position in Central Asia by establishing a new national subsidiary in Kyrgyzstan. With this step, the company is expanding its global network to 103 national subsidiaries and underscoring the strategic significance of the dynamically growing region. The new subsidiary in Bishkek will increase customer proximity and create the basis for better market access in an attractive economic</description>
</item>
<item>
<title>Partners Group Holding Ag: Arthur Law Named a 2026 World Economic Forum Young Global Leader</title>
<link>https://6ix.com/company/partners-group-holding-ag/news/arthur-law-named-a-2026-world-economic-forum-young-global-leader</link>
<guid isPermaLink="true">https://6ix.com/company/partners-group-holding-ag/news/arthur-law-named-a-2026-world-economic-forum-young-global-leader</guid>
<pubDate>Tue, 21 Apr 2026 02:00:00 GMT</pubDate>
<description>The KALE Foundation today announced that Arthur Law, Co-founder and Managing Principal of Storefriendly Asia, has been named a Young Global Leader 2026 by the World Economic Forum.</description>
</item>
<item>
<title>Molecular Partners Ag: Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712</title>
<link>https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin-mp0712</link>
<guid isPermaLink="true">https://6ix.com/company/molecular-partners-ag/news/molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin-mp0712</guid>
<pubDate>Sun, 19 Apr 2026 16:00:00 GMT</pubDate>
<description>MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3, half-life extension and DLL3 internalization for high tumor accumulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a</description>
</item>
<item>
<title>SEALSQ TO LAUNCH INDUSTRY’S MOST COMPREHENSIVE QUANTUM VERTICAL STACK FROM SILICON ROOT OF TRUST TO DISTRIBUTED QUANTUM COMPUTING AND ORBITAL CLOUD</title>
<link>https://6ix.com/news/sealsq-to-launch-industrys-most-comprehensive-quantum-vertical-stack-from-silicon-root-of-trust-to-distributed-quantum-computing-and-orbital-cloud-1</link>
<guid isPermaLink="true">https://6ix.com/news/sealsq-to-launch-industrys-most-comprehensive-quantum-vertical-stack-from-silicon-root-of-trust-to-distributed-quantum-computing-and-orbital-cloud-1</guid>
<pubDate>Thu, 16 Apr 2026 13:15:00 GMT</pubDate>
<description>SEALSQ’s end-to-end quantum ecosystem integrates hardware security, post-quantum cryptography, CMOS-compatible quantum processors, photonic interconnects, distributed sensing, and a 100-satellite orbital cloud, anchored by the $200 million SEALSQ Quantum FundGENEVA, SWITZERLAND , April 16, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or the “Company”), a global leader in post-quantum semiconductor and cybersecurity solutions and a subsidiary of WISeKey International Holding Ltd</description>
</item>
<item>
<title>Medmix Ag: medmix' Shareholders Approve All Proposals at Annual General Meeting 2026</title>
<link>https://6ix.com/company/medmix-ag/news/medmix-shareholders-approve-all-proposals-at-annual-general-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medmix-ag/news/medmix-shareholders-approve-all-proposals-at-annual-general-meeting-2026</guid>
<pubDate>Thu, 16 Apr 2026 12:37:00 GMT</pubDate>
<description>medmix AG Neuhofstrasse 20 CH-6430 Baar [email protected] www.medmix.swiss DOWNLOAD MEDIA RELEASE MEDIA RELEASE April 16, 2026 medmix’ Shareholders Approve All Proposals at Annual General Meeting 2026 At today’s annual general meeting (AGM) of medmix Ltd., shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.10 per share. Baar, Switzerland--(Newsfile Corp. - April 16, 2026) -...</description>
</item>
<item>
<title>Galderma Group N: Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-launches-new-alastin-regenerating-skin-nectar-with-trihextm-powered-by-its-next-generation-trihex-technologyr-regenerative-platform</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-launches-new-alastin-regenerating-skin-nectar-with-trihextm-powered-by-its-next-generation-trihex-technologyr-regenerative-platform</guid>
<pubDate>Thu, 16 Apr 2026 05:00:00 GMT</pubDate>
<description>ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with </description>
</item>
<item>
<title>Bioversys Ag: BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100</title>
<link>https://6ix.com/company/bioversys-ag/news/bioversys-announces-first-patient-first-visit-in-habpvabp-pivotal-phase-3-riv-target-trial-of-bv100</link>
<guid isPermaLink="true">https://6ix.com/company/bioversys-ag/news/bioversys-announces-first-patient-first-visit-in-habpvabp-pivotal-phase-3-riv-target-trial-of-bv100</guid>
<pubDate>Thu, 16 Apr 2026 05:00:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LRBASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) -- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected H</description>
</item>
<item>
<title>Basilea Pharmaceutica Ag: Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-2026-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-shareholders-approve-all-proposals-of-the-board-of-directors-at-the-2026-annual-general-meeting</guid>
<pubDate>Wed, 15 Apr 2026 16:30:00 GMT</pubDate>
<description>Allschwil, Switzerland, April 15, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM). Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carry</description>
</item>
<item>
<title>Partners Group Holding Ag: Lingerfelt and Partners Group Announce $175 Million Sale of 1.16 Million SF Industrial Portfolio</title>
<link>https://6ix.com/company/partners-group-holding-ag/news/lingerfelt-and-partners-group-announce-dollar175-million-sale-of-116-million-sf-industrial-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/partners-group-holding-ag/news/lingerfelt-and-partners-group-announce-dollar175-million-sale-of-116-million-sf-industrial-portfolio</guid>
<pubDate>Wed, 15 Apr 2026 11:00:00 GMT</pubDate>
<description>Lingerfelt, a vertically integrated real estate investment management firm, and Partners Group, one of the largest firms in the global private markets industry, today announced the successful sale of their 1.16 million square foot WalthallNorthlake Industrial Portfolio. The portfolio was sold to an undisclosed buyer for $175 million, or approximately $151 per square foot.</description>
</item>
<item>
<title>Cosmo Pharmaceuticals Sa: Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant</title>
<link>https://6ix.com/company/cosmo-pharmaceuticals-sa/news/phase-iii-12-month-data-for-clascoterone-5percent-topical-solution-confirm-positive-safety-for-chronic-use-and-continued-hair-growth-both-of-which-are-statistically-significant</link>
<guid isPermaLink="true">https://6ix.com/company/cosmo-pharmaceuticals-sa/news/phase-iii-12-month-data-for-clascoterone-5percent-topical-solution-confirm-positive-safety-for-chronic-use-and-continued-hair-growth-both-of-which-are-statistically-significant</guid>
<pubDate>Wed, 15 Apr 2026 05:07:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous Clascoterone treatment continued to gain hair through Month 12. In contrast, patients who switched to the placebo from Month 7 onwards experienced a reduction in treatment gains, demonstrating the importance of ongoing therapy. NDA and MAA preparations underway, U.S. filing planned...</description>
</item>
</channel>
</rss>